Compare PCRX & SLDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | SLDP |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 848.8M |
| IPO Year | 2010 | N/A |
| Metric | PCRX | SLDP |
|---|---|---|
| Price | $22.00 | $3.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $35.33 | $7.00 |
| AVG Volume (30 Days) | 739.7K | ★ 3.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $9.77 | $13.88 |
| Revenue Next Year | $9.71 | $10.00 |
| P/E Ratio | $142.97 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $0.68 |
| 52 Week High | $27.99 | $8.86 |
| Indicator | PCRX | SLDP |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 30.58 |
| Support Level | $20.41 | $2.92 |
| Resistance Level | $23.82 | $4.70 |
| Average True Range (ATR) | 1.00 | 0.19 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 43.41 | 3.29 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.